Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
[ad_1]
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020.
Mike Blake | Reuters
Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street's expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.
The drugmaker now expects full-year adjusted earnings of $13.50 to $14.00 per share, up from previous guidance of $12.20 to $12.70 per share. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range.
Analysts surveyed by LSEG expected full-year adjusted earnings of $12.50 per share and sales of $41.44 billion.
The company said the boosted guidance is in part due to optimism around increased production of Zepbound, Mounjaro and similar drugs for the rest of the year.
"Now that we're four months into the year, we have greater visibility into that, into these nodes of capacity and feel more confident," Eli Lilly CFO Anat Ashkenazi told investors during an earnings call Tuesday.
She noted that Eli Lilly has several manufacturing sites either "ramping up or under construction," including two locations in North Carolina, two in Indiana, one in Ireland and one in Germany, along with a seventh site the company recently acquired from Nexus Pharmaceuticals.
Eli Lilly said demand for Mounjaro and Zepbound — treatments known as incretin drugs, which mimic hormones produced in the gut to suppress a person's appetite and regulate their blood sugar — outpaced increases in supply during the quarter. And the company expects supply to remain "quite tight" in the near- to mid-term amid continued demand for those drugs, Ashkenazi said.
But Eli Lilly expects the most significant production increases expected in the second half of the year, she noted.
"Our top priority is making more product, and we're doing everything we can to do that," Eli Lilly CEO David Ricks said in an interview Tuesday on CNBC's "Squawk Box." "We're ramping that aggressively. But it's capital intensive, it's technically complex and highly regulated."
The results and guidance raise reflect Zepbound's first full quarter on the U.S. market after winning approval from regulators in early November. The drug reported $517.4 million in sales for the first quarter, even as most doses of the drug slipped into shortages in the U.S. that are expected to last through June.
Analysts say the weekly injection could post more than a billion dollars in sales in its first year on the market and potentially become the biggest drug of all time.
Here's what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: $2.58 adjusted vs. $2.46 expected
- Revenue: $8.77 billion vs. $8.92 billion expected
Eli Lilly posted net income of $2.24 billion, or $2.48 a share, for the first quarter. That compares with a profit of $1.34 billion, or $1.49 a share, a year earlier.
Excluding one-time items associated with the value of intangible assets, among other adjustments, the company posted a per-share profit of $2.58 for the first quarter of 2024.
The pharmaceutical giant booked first-quarter revenue of $8.77 billion, up 26% year over year.
Shares of Eli Lilly jumped more than 5% on Tuesday. The stock is up 26% this year after surging almost 60% in 2023 due to the insatiable demand for the company's weight loss and diabetes drugs. That's despite their hefty price tags, spotty insurance coverage and intermittent supply shortages.
With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.
Mounjaro, Trulicity results
Both of the company's top-selling diabetes drugs missed Wall Street's expectations for the first quarter.
Mounjaro brought in $1.81 billion in revenue in the first quarter, more than triple the $568.5 million it booked during the year-earlier period. However, analysts were expecting sales of $2.11 billion, according to StreetAccount.
Eli Lilly said higher prices for Mounjaro helped drive up revenue, specifically citing decreased use of savings card programs for the drug in the U.S.
But the company said those savings card dynamics should "cease to have a notable effect on realized price comparisons" because the $25 monthly coupon for patients who don't have insurance coverage for Mounjaro expired in June.
"From the second half of each year, we should expect to see typical pricing for Mounjaro," Patrik Jonsson, Eli Lilly's executive vice president of diabetes and obesity, said during the call on Tuesday.
Meanwhile, sales of Eli Lilly's older diabetes drug Trulicity plummeted 26% during the first quarter to $1.46 billion. That's lower than the $1.59 billion that analysts were expecting, according to StreetAccount.
In the U.S., declining sales were primarily due to supply constraints and competition with other diabetes treatments, according to Eli Lilly. Revenue outside the U.S. also decreased, driven by lower demand and realized prices, as well as tight supply.
Other drugs miss expectations
Revenue growth was also driven by sales of Eli Lilly's breast cancer pill Verzenio, which rose 40% to $1.05 billion for the quarter due to increased demand.
Those results came in under analysts' expectations, however, which called for $1.11 billion in sales for the period.
Sales of Jardiance, a tablet that lowers blood sugar in Type 2 diabetes patients, climbed 19% to $686.5 million for the first quarter. Analysts had expected $718.3 million in sales from Jardiance.
Jardiance, which Eli Lilly shares with Boehringer Ingelheim, is among the first 10 drugs selected to face price negotiations with the federal Medicare program.
Comments
Post a Comment